<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00984646</url>
  </required_header>
  <id_info>
    <org_study_id>RN1003-0027</org_study_id>
    <nct_id>NCT00984646</nct_id>
  </id_info>
  <brief_title>Investigation Into the Scar Reduction Potential of Prevascar (Interleukin-10)</brief_title>
  <official_title>A Single-centre, Placebo- and Standard-care-controlled, Double-blind, Randomised Trial to Investigate the Efficacy of Eight Doses of RN1003 in the Reduction of Scarring From the Approximated Wound Margins of Incisional Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Renovo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Renovo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to investigate the scar-reducing properties of eight doses of&#xD;
      intradermal Prevascar (IL-10).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects were randomised to one of two dose groups, each with four concentrations of&#xD;
      intradermal Prevascar. Subjects had four 1cm incisional wounds made on the inner aspect of&#xD;
      each upper arm (eight in total), giving four sets of anatomically paired wound sites per&#xD;
      subject. Each subject acted as their own control with one site from each wound pair randomly&#xD;
      treated with intradermal Prevascar and the other treated with Placebo (vehicle) or Standard&#xD;
      Care.&#xD;
&#xD;
      Intradermal Prevascar was administered at 100μl per linear cm of wound site prior to wounding&#xD;
      on Day 0 and 100μl per linear cm to each wound margin 24 hours later on Day 1. Group 1&#xD;
      subjects received doses of 5, 50, 250 and 1000ng/100μl and group 2 subjects received 25, 125,&#xD;
      500 and 2000ng/100μl.&#xD;
&#xD;
      Subjects in each group were also randomised into two control subgroups to receive either&#xD;
      100μl/linear cm intradermal placebo (Subgroup 1) or Standard Care alone (Subgroup 2) at&#xD;
      control wound sites.&#xD;
&#xD;
      Subjects returned for follow-up at Day 14, Month 1, Month 3, Month 6, Month 9 and Month 12.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish which of eight intradermal doses of RN1003 has the greatest scar-reducing properties, compared with Placebo and Standard Care.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To collect further safety and tolerability data for RN1003</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess pre- and post-dose systemic levels of RN1003.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">175</enrollment>
  <condition>Cicatrix</condition>
  <condition>Wound Healing</condition>
  <arm_group>
    <arm_group_label>Intradermal Prevascar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (vehicle)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prevascar</intervention_name>
    <description>Intradermal Prevascar, 5ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later</description>
    <arm_group_label>Intradermal Prevascar</arm_group_label>
    <other_name>IL-10</other_name>
    <other_name>Ilodecakin</other_name>
    <other_name>RN1003</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prevascar</intervention_name>
    <description>Intradermal Prevascar, 50ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later</description>
    <arm_group_label>Intradermal Prevascar</arm_group_label>
    <other_name>IL-10</other_name>
    <other_name>Ilodecakin</other_name>
    <other_name>RN1003</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prevascar</intervention_name>
    <description>Intradermal Prevascar, 250ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later</description>
    <arm_group_label>Intradermal Prevascar</arm_group_label>
    <other_name>IL-10</other_name>
    <other_name>Ilodecakin</other_name>
    <other_name>RN1003</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prevascar</intervention_name>
    <description>Intradermal Prevascar, 1000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later</description>
    <arm_group_label>Intradermal Prevascar</arm_group_label>
    <other_name>IL-10</other_name>
    <other_name>Ilodecakin</other_name>
    <other_name>RN1003</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prevascar</intervention_name>
    <description>Intradermal Prevascar, 25ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later</description>
    <arm_group_label>Intradermal Prevascar</arm_group_label>
    <other_name>IL-10</other_name>
    <other_name>Ilodecakin</other_name>
    <other_name>RN1003</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prevascar</intervention_name>
    <description>Intradermal Prevascar, 125ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later</description>
    <arm_group_label>Intradermal Prevascar</arm_group_label>
    <other_name>IL-10</other_name>
    <other_name>Ilodecakin</other_name>
    <other_name>RN1003</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prevascar</intervention_name>
    <description>Intradermal Prevascar, 500ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later</description>
    <arm_group_label>Intradermal Prevascar</arm_group_label>
    <other_name>IL-10</other_name>
    <other_name>Ilodecakin</other_name>
    <other_name>RN1003</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prevascar</intervention_name>
    <description>Intradermal Prevascar, 2000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later</description>
    <arm_group_label>Intradermal Prevascar</arm_group_label>
    <other_name>IL-10</other_name>
    <other_name>Ilodecakin</other_name>
    <other_name>RN1003</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intradermal Placebo, 100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later</description>
    <arm_group_label>Placebo (vehicle)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects, aged 18-85 years, who have given written informed consent&#xD;
&#xD;
          -  Subjects with a BMI (Quetelet's index) within the permitted weight/height2 range of&#xD;
             15-55kg/m2&#xD;
&#xD;
          -  Subjects with, in the opinion of the Investigator, clinically acceptable results for&#xD;
             screening laboratory tests performed within 28 days prior to the first trial&#xD;
             administration&#xD;
&#xD;
          -  Female subjects with child-bearing potential who are using a method(s) of&#xD;
             contraception deemed acceptable by the Investigator and agree to continue doing so for&#xD;
             the first month of the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who, on direct questioning and by physical examination, reveal a history or&#xD;
             evidence of hypertrophic or keloid scarring&#xD;
&#xD;
          -  Subjects with tattoos or previous scars within 3cm of the area to be incised during&#xD;
             the trial&#xD;
&#xD;
          -  Subjects of Afro-Caribbean descent, because of their increased susceptibility to&#xD;
             hypertrophic or keloid scarring&#xD;
&#xD;
          -  Subjects who have had previous surgery in the area to be incised, conducted within 1&#xD;
             year of the first dosing day&#xD;
&#xD;
          -  Subjects with a history of a bleeding disorder or who are receiving anticoagulant&#xD;
             therapy&#xD;
&#xD;
          -  Subjects who, on direct questioning and physical examination, show evidence of any&#xD;
             past or present clinically significant disease that may affect the endpoints of the&#xD;
             trial, e.g. coagulation disorders, diabetes, immuno- mediated conditions and&#xD;
             clinically significant skin diseases or allergies&#xD;
&#xD;
          -  Subjects with a clinically significant skin disorder that is chronic or currently&#xD;
             active, and which the Investigator considers will adversely affect the healing of the&#xD;
             acute wounds or involves the areas to be examined in this trial&#xD;
&#xD;
          -  Subjects with any clinically significant medical condition or history that would&#xD;
             impair wound healing, including significant rheumatoid arthritis, chronic renal&#xD;
             impairment (significant for age), significant hepatic impairment (liver function tests&#xD;
             &gt;3 times upper limit of normal), congestive heart failure, active malignancy or&#xD;
             history of malignancy within last 5 years, immunosuppression or chemotherapy within&#xD;
             last 12 months, history of radiotherapy or diabetes mellitus&#xD;
&#xD;
          -  Subjects with a history of hypersensitivity to any of the drugs or dressings used in&#xD;
             the trial&#xD;
&#xD;
          -  Subjects who are taking, or who have taken, any investigational product or&#xD;
             participated in a clinical trial within 3 months prior to the first trial&#xD;
&#xD;
          -  dose administration&#xD;
&#xD;
          -  Subjects who are taking regular, continuous, oral corticosteroid therapy&#xD;
&#xD;
          -  Subjects undergoing investigations or changes in management for an existing medical&#xD;
             condition&#xD;
&#xD;
          -  Subjects with a history of drug abuse, or who test positive for drugs of abuse&#xD;
             (cocaine, amphetamines, methamphetamines, opiates or benzodiazepines) during the&#xD;
             screening period, which is not explained by the intake of legitimate prescribed or&#xD;
             over-the-counter medication for a documented medical condition&#xD;
&#xD;
          -  Subjects who, in the opinion of the Investigator, are unlikely to complete the trial&#xD;
             for whatever reason&#xD;
&#xD;
          -  Subjects receiving immunosuppressive treatment&#xD;
&#xD;
          -  Females who are pregnant or lactating&#xD;
&#xD;
          -  Subjects who have any clinically significant neurological impairment or disease&#xD;
&#xD;
          -  Subjects with an active infection (subjects were able to participate in the trial once&#xD;
             the infection had passed and they had been re-screened)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Bush</last_name>
    <role>Principal Investigator</role>
    <affiliation>Renovo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Renovo</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>September 24, 2009</study_first_submitted>
  <study_first_submitted_qc>September 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2009</study_first_posted>
  <last_update_submitted>September 24, 2009</last_update_submitted>
  <last_update_submitted_qc>September 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>John Hutchison</name_title>
    <organization>Renovo</organization>
  </responsible_party>
  <keyword>Cicatrix</keyword>
  <keyword>Scar</keyword>
  <keyword>Wound-healing</keyword>
  <keyword>Prevascar</keyword>
  <keyword>Interleukin-10 (IL-10)</keyword>
  <keyword>Ilodecakin</keyword>
  <keyword>RN1003</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cicatrix</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

